|Other Names||Integral membrane protein 2C, Cerebral protein 14, Transmembrane protein BRI3, CT-BRI3, ITM2C, BRI3|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Negative regulator of beta amyloid peptide production. May inhibit the processing of APP by blocking its access to alpha- and beta-secretase. Binding to the beta-secretase-cleaved APP C- terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation (By similarity).|
|Cellular Location||Lysosome membrane; Single-pass type II membrane protein. Cell membrane; Single-pass type II membrane protein|
|Tissue Location||High levels in the brain, specifically in the cerebral cortex, medulla, amygdala, hippocampus, thalamus, caudate nucleus, cerebellum, olfactory lobe and spinal cord. Very low levels in other organs.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Negative regulator of beta amyloid peptide production. May inhibit the processing of APP by blocking its access to alpha-and beta-secretase. Binding to the beta-secretase-cleaved APP C-terminal fragment is negligible, suggesting that ITM2C is a poor gamma-secretase cleavage inhibitor. May play a role in TNF-induced cell death and neuronal differentiation (By similarity).
Yoshida, T., et al. Int. J. Mol. Med. 25(4):649-656(2010)Oguri, M., et al. Am. J. Hypertens. 23(1):70-77(2010)Matsuda, S., et al. J. Biol. Chem. 284(23):15815-15825(2009)Matsuda, S., et al. Mol Neurodegener 4, 41 (2009) :Gong, Y., et al. BMB Rep 41(4):287-293(2008)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.